ImmuneID Advances Precision Immunology Strategy with New Leadership at the Helm

ImmuneID, a precision immunology company advancing the science of antibody interaction identification and therapeutic targeting for immune diseases, has unveiled a significant leadership transition designed to accelerate its path to developing transformational therapeutics. The company has named James S. Scibetta to the role of Chief Executive Officer and Board Member, effective immediately.

Strategic Vision Meets Proven Execution

Scibetta arrives at ImmuneID with an impressive biotech pedigree spanning more than two decades. His career trajectory includes leading Maverick Therapeutics—where he guided the organization through its acquisition by Takeda in April 2021—and holding multiple executive positions at Pacira Pharmaceuticals (Nasdaq: PCRX), where he drove the company’s 2011 IPO and steered global R&D and manufacturing strategy for their flagship product EXPAREL.

“The human immune system represents one of the most intricate biological systems we know, driving the pathology across a vast spectrum of diseases,” Scibetta stated. “ImmuneID’s proprietary technology—born from the laboratory of Harvard professor and Lasker Award-winning researcher Dr. Steve Elledge—generates an unprecedented volume of biologically meaningful human immune response data. Combined with cutting-edge AI and machine learning capabilities, this positions ImmuneID to pioneer the next wave of precision immunology treatments for autoimmune conditions, allergies, malignancies, and infectious diseases.”

Building on Existing Momentum

David Donabedian, Ph.D., who had been serving as CEO since the company’s Q4 2020 launch, will transition to an advisory capacity. Under Donabedian’s stewardship, ImmuneID successfully raised over $70 million, assembled a world-class scientific team, and established cutting-edge laboratory facilities in Cambridge, Massachusetts.

“Jim’s track record in translating sophisticated science into patient-focused therapeutic solutions is unparalleled,” said Christoph Westphal, M.D., Ph.D., ImmuneID co-founder and Board Chair at Longwood Fund. “His demonstrated expertise in corporate strategy, capital formation, and building high-performing cross-functional teams across research, bioinformatics, manufacturing, and commercialization will be instrumental as ImmuneID scales its platform to address diseases with profound unmet medical needs in the immune space.”

Technology Foundation and Platform Capabilities

ImmuneID’s platform integrates next-generation sequencing with robust protein display technologies to comprehensively map patient antibody-target interactions in immune-mediated conditions. The underlying technology, originally developed in Stephen Elledge’s Harvard laboratory, generates millions of antibody-target interaction data points to systematically build the landscape of human immune response throughout disease progression.

About the Company

Founded in late 2020 by Longwood Fund, ImmuneID operates from its Cambridge headquarters, where it combines rigorous bench science with advanced computational biology and large-scale data generation to advance personalized diagnostics and precision treatments for immune-mediated diseases.

Prior to joining ImmuneID, Scibetta held the position of CFO at Bioenvision Inc. (NASD: BVIN, acquired by Genzyme) and Merrimack Pharmaceuticals. His early career involved over a decade in investment banking, sourcing and executing transactions across public and private healthcare and life sciences entities. He holds a B.S. in physics from Wake Forest University and an MBA from the University of Michigan.